A B S T R A C T The antihypertensive drug hydralazine can induce in man a syndrome similar to spontaneous systemic lupus erythematosus (SLE). The pathogenesis of this drug-induced syndrome is not understood. In this investigation, five groups of rabbits were studied: group I, 10 rabbits hyperimmunized with hydralazine conjugated to human serum albumin (HSA) 
INTRODUCTION
In the large majority of patients with systemic lupus erythematosus (SLE),' no specific etiological factor can be identified. However, after the administration of certain drugs, a small number of patients develop symptoms and signs which closely resemble those found in agent, is one of the major drugs which can induce an SLE-like syndrome. It does so in approximately 7-13% of the patients chronically treated (7, 8) . However, though we know the provocative agent, the possible pathogenetic mechanisms remain obscure with the sole exception that hydralazine antibodies have been reported in these patients (3, 9) .
Unfortunately, to date animal experiments with hydralazine have not proven any more illuminating than human studies. Indeed, many conflicting results have been obtained. Even in experiments where ANA and/or LE cells were produced, pathological findings were equivocal or no data were provided to account for the production of serological findings.
Recently, we have succeeded in covalently binding hydralazine and one of its major urine metabolites (10) to human serum albumin (HSA) and rabbit serum albumin (RSA). The present study was undertaken to evaluate the immunological and pathological effects produced by immunization of rabbits with these compounds.
METHODS
New Zealand white rabbits weighing 1.5 kg initially and fed standard Purina rabbit chow were used in this study. For 24-h urine collections, the rabbits were placed in metabolic cages with free access to water and the urines collected for 24, 48, and, in some cases, 72 h. The 24-h urinary total protein excretion was measured by the method of Shevky and Stafford ( 11 ) .
Synthesis of the compounds of hydralazine and HSA and RSA were as follows: a solution of p-nitrophenol pyruvate hydralazone (1.4 mg, 4.0 X 10' M) in 0.5 ml of tetrahydrofurane was added via a syringe to a stirred solution of HSA (276 mg, 4 X 10-' M) (Miles Laboratories, Inc., Kankakee, Ill.) in 5.0 ml of pH 9.2 borax buffer (0.025 M) at room temperature. The cloudy solution was stirred at room temperature until it became clear (about 90 min) and allowed to stand at 4°C for 16 h. Purification was accomplished by prolonged dialysis (4-7 days) at 4°C against several changes of 2 N sodium chloride solution, followed by several changes of pH 8.2 phosphate buffer (5 X 10-' M) until complete removal of p-nitrophenol was achieved. At this time, the dialysates did not indicate the presence of the phenol according to UV analysis. Lyophilization of the dialysates was carried out, resulting in a light yellow powder. The extent of conjugation was estimated from the UV spectrum at 353 nm. By using the extinction coefficient of the pyruvic acid hydralazone at 353 nm, the number of residues of the hydralazone was calculated to be about 1. By using appropriate amounts of the pyruvic acid hydralazone in the above procedure, conjugates were prepared with binding ratios of 1: 1, 3: 1, 6: 1, 15: 1, and 25: 1. Similarly, a conjugate was paired with RSA (Miles Laboratories, Inc.) with a binding ratio of 25: 1. These compounds will be referred to subsequently as "hydralazine-HSA" and "hydralazine-RSA." The subscript with hydralazine will refer to the number of moles of hapten per mole of carrier.
The main urinary metabolite of hydralazine is 3-methyls-triazolo [3,4-a] phthalazine (12) . Since this molecule does not possess a functional group via which it could be covalently conjugated to HSA or RSA, it was structurally altered slightly to permit it to be chemically bound to a protein. The compound chosen for this purpose was 2-(striazolo [3,4-a] phthalazinyl) propionic acid (13) . Conjugation was achieved in a manner similar to the above method. Thus, to a solution of HSA, 500 mg (7.25 X 10' MW) in 50 ml of pH 9.2 borax buffer was added to powdered 4-nitrophenyl 2-(3-s-triazolo [3,4-a] phthalazinyl propionate), 68 mg (1.94 X 10' M). The mixture was stirred 48 h at room temperature and buffered. The filtrate was concentrated by lyophilization and purified as above. The extent of conjugation was estimated by analysis of the UV spectrum of the conjugate. The extinction coefficient of the substituted propionic acid at 241 nm (4.33 X 103) was used. The binding ratio of triazolophthalazine per molecule of HSA was calculated to be about 6: 1. In an analogous manner, the RSA conjugate was prepared. These compounds will be referred to subsequently as "metabolite-HSA" and "metabolite-RSA." The subscript with metabolite will refer to the number of moles of hapten per mole of carrier.
Various molar ratios of hydralazine conjugated to HSA were tested for immunogenicity before the present experiments. The compounds tested ranged from hydralazine6-HSA to hydralazinez-HSA. The latter proved the most immunogenic as measured by precipitating antibodies. At the start of the experiment, the highest molar ratio of metabolite to HSA that could be synthesized was 6: 1, and a compound with this ratio was used in these experiments as an immunogen. Later, higher molar ratios could be achieved and metabolite15-RSA was used as described below for determining hydralazine metabolite antibodies.
Hydralazine antibodies were determined by microadaptation of the passive hemagglutination test of Boyden with tanned sheep red blood cells coated with hydralazine25-RSA (14, 15) . As all rabbits in each group failed to recognize RSA immunologically, this test measured only antihydralazine antibodies. Antibodies to metabolite6-HSA were measured in similar fashion except that the sheep erythrocytes were coated with metabolite15-RSA. Inhibition studies were performed by adding 50 jig of the inhibitor to each well on the microtiter plate and then carrying out the titer as above. The compounds used for inhibition included hydralazine HCl, hydralazines-RSA, hydralazine25-HSA and metabolitev5-RSA. Anti To exclude the possibility that the antibodies being detected by the "native" DNA-binding assay were not to the small areas of single-strandedness known to exist in commercial DNA (18, 19) but to the double-stranded structure of native DNA, native DNA (Worthington Biochemical Corp.) was digested with an exonuclease isolated from Neurospora crassa conidia (Miles Laboratories, Inc.), an enzyme which has been demonstrated to be specific for single-stranded DNA (prepared by heat) and which does not attack DNA in the native form (20, 21 ANA were determined by using normal rabbit peripheral white cells as a substrate with a fluoresceinated goat antirabbit IgG antiserum at a concentration of 3 mg/ml. The antiserum was prepared and labeled in this laboratory.
IgG fractions of sera from seven rabbits were purified by using DEAE-cellulose chromatography (24) and assessed for DNA binding activity and hydralazine hemagglutinins as described above.
All antibody assays were performed with serum heated at 56°C for 30 min with some repeated with the same serum heated at 560C for 60 min. The additional 30-min heating did not produce any appreciable changes in the results.
At the time of sacrifice, tissues were taken for histopathological studies including routine hematoxylin and eosin and periodic acid-Schiff stains of the tissue sections. Some tissues were snap frozen for immunofluorescent studies.
The experimental design involved five (5) groups of rabbits. Group I consisted of 10 rabbits immunized at 2-wk intervals until the 12th wk with hydralaziner,-HSA in complete Freund's adj uvant (CFA). One additional injection was given at the 17th wk. The initial dose was 10 mg of hydralazine-s-HSA in CFA divided between the hind foot pads. Subsequent injections consisted of 5 mg of hydralazine2z-HSA in CFA injected subcutaneously into the back and neck. In group II, there were four rabbits immunized with HSA in CFA after a similar dosage and injection schedule. In group III were four rabbits which received CFA alone on a similar schedule. In group IV, five rabbits were immunized with hydralazine2rs-RSA in CFA after a similar dosage and injection schedule. Group V consisted of four rabbits immunized with metabolite6-HSA again on a similar schedule and manner as the other groups. The data obtained from animals in groups II and III were similar and have been combined and referred to subsequently as the "controls." The mean and standard deviations for the DNA binding assays were determined by the unpaired t test. A paired t test was used to compare intragroup differences (25) . Fig. 1 shows the mean hydralazine antibody titer from each group. Only rabbits immunized with hydralazine25-HSA, hydralazine25-RSA, or metabolites-HSA developed significant titers of hydralazine antibodies as measured by hemagglutination. After the sixth inj ection, titers ceased to rise despite continuing immunization. When first measured at 4 wk, a time by which two injections had been administered, the antibody titers in the hydralazine25-HSA, hydralazine25-RSA, and the metabolite6-HSA groups were resistant to 2-mercaptoethanol, indicating that the antibodies were primarily IgG. The antibody titers against hydralazine in the metabolite6,-HSA-immunized group of rabbits are indicative of the cross-reactivity between hydralazine and its major urinary metabolite. Inhibition studies of the hydralazine antibody titers were done with the sera obtained at the termination of the experiment (22 wk) groups of rabbits also had low titers of antibody to metabolitel5-RSA, again indicating the cross-reactivity that exists between hydralazine and its metabolite. Fig. 2 illustrates the mean binding antibody titers to [RH] single-stranded calf thymus DNA. Significant binding is limited to the metabolitea-HSA and the hydralazine25-HSA groups. By the 4th wk, 4 rabbits in the latter group exceeded the mean ±2 SD of the controls, and by the 8th wk, 9 of 10 did. The difference between the hydralazine25-HSA group and the controls continued to increase until the 12th wk. The additional injection on the 17th wk produced a further rise in binding. Three of four rabbits immunized with metabolite3-HSA exhibited significant binding by the 4th wk and by the 12th wk, all four animals had binding that was significantly increased as compared to the controls. The position of the final point in Fig. 2 of the 22 wk binding of the metabolitea-HSA group is doubtful. One rabbit died before being bled and at that time another rabbit which had had a small but significant amount of binding to single-stranded DNA no longer had detectable antibodies to single-stranded DNA. No response was noted in the hydralazine25-RSA group, implying a major role for the carrier protein in the production of DNA antibodies.
RESULTS
In the hydralazine25-HSA group, 9 of 10 rabbits had precipitating antibodies at the 22nd wk of immunization to one or more of the various types of single-stranded DNA tested which included calf thymus, salmon sperm, and M. lysodeikticus. Precipitins to single-stranded DNA were detected in three of four of the metabolitea-HSA group of animals. These precipitin lilnes were not observed when the serum had been previously absorbed with single-stranded DNA.
The mean binding antibodies to [3H]calf thymus native DNA is seen in each group in Fig. 3 . Only the hydralazine25-HSA-immunized rabbits and metabolite6-HSA rabbits show significant binding. In the former group, three rabbits had significantly elevated levels of antibodies to native DNA 4 wk after beginning immuniInduction of Antibodies to Nuclear Antigens by Hydralazine-HSA zation. By 8 wk, six rabbits had some increase in binding although this was borderline in three. The amount of binding continued to rise in these six rabbits until by 22 wk, two had between 10 and 15% binding, three between 15 and 21% binding, and one 53% binding. The mean ±2 SD of the controls at this time was 6.3±1.8%.
By a paired t test, the native DNA binding of the preimmunization sera compared to the 22-wk sera showed a significant increase for the group as a whole with a P value of < 0.025. The rise in antibodies to native DNA found in the metaboliteB-HSA animals was similar to that observed in the hydralazine2z-HSA group of Tests for antinuclear factor were performed with sera obtained on the terminal bleed. These were positive in 8/10 of the hydralazine2s-HSA-immunized group and in 2/4 of the metabolitee-HSA group. In the hydralazine25-HSA group, six had a titer of at least 1: 8 and two 1: 4. In the metabolite6-HSA group, both rabbits had a titer of 1: 8. The titers were not taken to higher levels. The ests were negative in the controls and in the hydralaine25-HSA-immunized rabbits. IgG fractions were isolated from the 22-wk sera of our hydralazine25-HSA-immunized rabbits, two HSAmmunized rabbits, and one CFA-immunized rabbit. The durity of the fractions was verified by immunoelectrophoresis against a goat anti-rabbit whole serum. The fractions were studied for hydralazine hemagglutinins and DNA binding activity with the results illustrated in Table VI . Only the fractions from the hydralazine25-HSA-immunized rabbits had high titers of hydralazine antibodies and DNA binding activity, proving that both of these tests were mediated by an IgG antibody. The hydralazine antibody titers in the IgG fractions were disproportionately elevated as opposed to the titers found in the whole serum. The reason for this disproportionate elevation is not clear. After 22 wk, the rabbits in each group were sacrificed and autopsies performed. No gross anatomical differences were noted between the various groups. Light microscopy showed no significant changes, except for one rabbit which exhibited slight thickening of the glomerular basement membrane. This was the rabbit in the hydralazine2z-HSA-immunized group which exhibited the highest native DNA binding activity. However, immunofluorescence of the kidneys of this rabbit and of all rabbits in each group were negative for the presence of IgG antibodies.
DISCUSSION
Because of the relationship of hydralazine to the induction of SLE in man and the need for a laboratory model of SLE, many investigators have sought to duplicate this clinical syndrome in animals. Such experiments have yielded a variety of results. Initally, in 1956, Comens reported the production of positive LE cells, renal glomerular lesions, (wire-loop), and some hematologic changes as well as cachexia, convulsions, and death in dogs receiving oral hydralazine (27) . Symptoms occurred within a few weeks to a few months. Seven of the eight dogs had LE cells and in 2 cases the appearance of LE cells was confirmed by Hargreaves himself. However, neither Gardner nor Dubois et al. were able to reproduce this experiment except for the toxic reactions and some hematological abnormalities observed by Gardner (28, 29) . LE-like cells were observed by Gardner but were very atypical, still retaining some nuclear structure. The same negative results were found by Mollerberg in rats and McCoy and Leach in pigs given oral hydralazine (30, 31) . In 1958, Singuier et al., administering hydralazine orally, found that 4 of 15 guinea pigs developed "classic" LE cells, three others LE-"like" cells, anemia, and leukopenia, but the animals were not studied histologically (32) . Braverman and Lerner in 1962 repeated this experiment, using a variety of regimens, but with most animals receiving 100 mg hydralazine/kg (33) . 17% of the animals receiving hydralazine had LE-"like" cells in which the inclusion bodies were not liomogeneous. On l)ostmiiortem exaniniiation, no significanit changes were nioted except for iminiimal thickening of the glomerular basement membrane in some guinea pigs, but this finding was not considered to be significantly different from that observed in normal guinea pigs. In 1967, Le6vey (35) . They detected antibodies to hydralazine, using passive cutaneous anaphylaxis and the Farr technique employing`25I-hydralazine5-ovalbumin. A marked strain difference was noted in that strain 2 guinea pigs were low responders whereas strain 13 and Hartley guinea pigs were high responders. Delayed hypersensitivity also developed to hydralazine. No differences were noted in the hepatic acetylation rate between strain 2 In the present studies, the results obtained partially clarify this hitherto ill-understood relationship of hydralazine and SLE. A number of the problems concerning the mechanism of induction of SLE by hydralazine were at least in part resolved. First, hydralazine (and one of its major metabolites) was administered only as an immunogen, i.e., covalently attached to a carrier protein. This mode of presentation of hydralazine to the animal together with the fact that the total amount of hydralazine administered was miniscule (approximately 3.7 mg total dose) would implicate an immune reaction to hydralazine as being responsible for the production of DNA antibodies rather than a "toxic" effect. Secondly, as apparent from inspection of the data on DNA antibodies (Figs. 2 and 3) , continued immunization with hydralazine attached to a carrier was required, even while incorporating it in CFA. This need for hyperimmunization has been overlooked by many previous investigators and is in accordance with the observation that the average patient who develops hydralazine-SLE requires an average of 17 mo exposure to the drug (2) . One difference found between this study and human drug-induced SLE is that the antibodies directed to DNA in the rabbits were to both the native and denatured forms. The amount of antibodies to native DNA produced in at least one rabbit was unexpectedly high. The conclusion that antibodies were produced to the native form of DNA is based on the results of DNA hemagglutination tests and binding of [3H] native DNA by the Farr technique as well as by specific inhibition of these tests. Further, the binding was confirmed to be to native DNA as demonstrated in the experiment where native DNA was treated with an exonuclease which is specific for single-stranded DNA. Similar results in the binding assay were also obtained with a highly purified deproteinized DNA.
Another major difference between the human druginduced disease and the findings in this experiment is that histological changes were not observed in the rabbits. However, this point must be qualified because the possibility exists that such changes might have appeared if the injections of hydralazine25-HSA and metaboliteo-HSA had been continued for a longer period of time. The antibody titers to both single-stranded and native DNA were continuing to rise when the experiment was terminated. Thirdly, the uncovering of the immunologic cross-reactivity existing between hydralazine and DNA is perhaps the most important observation made in this study. Initially this was suggested by the findings in double diffusion in agarose gel (Fig. 4) and confirmed by absorption studies of the DNA binding assays, inhibition of DNA hemagglutination tests by the hydralazine compounds and hydralazine itself, and finally by inhibition of hydralazine antibody titers by native DNA. The population of antibodies to DNA that are cross-reactive with hydralazine is likely to be quite small, as was suggested by the limited inhibition of hydralazine antibody titers with native DNA and by the thinness of the cross-reactive line between singlestranded DNA and hydralazines-RSA noted in the double diffusion in agarose studies.
It is of interest that immunization with hydralazine linked to an isologous protein (RSA) failed to produce DNA antibodies but yielded hydralazine antibodies in amounts equal to those found in rabbits immunized with hydralazine attached to an heterologous protein (HSA). Because the hydralazine antibodies produced in the hydralazine25-RSA group were IgG antibodies and were hapten specific, it is suggested but not proven in these experiments that helper thymus-derived (T) lymphocytes were involved. Walters, Moorhead, and Claman have shown that haptens attached to an isologous carrier protein administered to mice in CFA are immunogenic involving helper T lymphocytes directed against both the hapten and the hapten-carrier conjugate but not against the carrier alone (39, 40). The question then arises as to why these antihydralazine antibodies in the hydralazine2s-RSA-immunized rabbits were not cross-reactive with DNA. One could postulate that there is a definite requirement for T lymphocytes directed against the carrier alone in order for a highly crossreactive population of hydralazine antibodies to be produced or that when such carrier directed T lymphocytes are activated, suppressor T lymphocytes which inhibit the production of antibodies to hydralazine which are cross-reactive with DNA are overcome. The data obtained in these experiments do not provide answers for these questions. They only emphasize the importance of an immune reaction occurring to a carirer protein.
The group of animals immunized with metabolitee-HSA was smaller in number than that immunized with hydralazine.s-HSA. However, the findings were quite similar. Antibodies induced by the metabolite crossreacted with hydralazine as well as with both the native and single-stranded DNA. Because the inhibition of the binding assay with hydralazinez-RSA was quite similar to that found with metabolite6-HSA, it is suggested that the antigenic determinant that induced DNA antibodies is common to both of these compounds. Most likely, this common antigen determinant resides in the similar phthalazine ring structure.
Although many problems concerning the relationship between hydralazine and DNA were resolved by this study, the question whether autoimmunity was truly established in the rabbits immunized with hydralazines-HSA and metabolitee-HSA was not settled. Autoantibodies other than those directed against nuclear antigens were not sought. The antibodies to nuclear antigens which were detected may represent a subpopulation of antihydralazine antibodies which are cross-reactive with the nuclear antigens. This was suggested by the virtual complete removal of DNA binding activity in the sera of these rabbits by absorption of the sera with hydralazine or its compounds. It remains for future studies to resolve this point.
Extrapolation of the findings in this experiment can be made to human SLE. In accord with the theory of autoimmunity proposed by Weigle which is supported by his experimental observations, he has shown that for most self-antigens, T lymphocytes have a long duration of immune tolerance whereas in the bone marrow-derived (B) lymphocytes, the duration of immune tolerance is quite limited (41) . B-cell clones are continually arising which can react with self-antigens if a T-cell signal is given. Therefore, if the native antigen is altered or exposure is made to another closely related yet foreign antigen, tolerance to the native antigen is then abolished by T-cell stimulation, and immune response with antibody production can ensue. A prime example of this is the induction of thyroiditis by Weigle. Rabbits have circulating low levels of thyroglobulin which he considers sufficient to maintain T-cell unresponsiveness but not B-cell unresponsiveness (42) . Therefore, clones of B cells responsive to thyroglobulin are continually arising. When he injected native thyroglobulin into rabbits, neither antibody formation nor thyroiditis occurred (43) . If he injected altered or cross-reactive thyroglobulin into rabbits, then the rabbits not only made antibodies to thyroglobulin, but also thyroiditis appeared. Once the unresponsive state was terminated, further injections of thyroglobulin continued to increase antibody levels to thyroglobulin and the severity of thyroiditis (44) . However, the antibodies produced were to antigenic determinants which were indigenous to the heterologous thyroglobulin since all the antibodies produced to thyroglobulin, even after injection of native thyroglobulin, could be completely absorbed with the heterologous thyroglobulin (45) . If the injections of native thyroglobulin were continued, the rabbits soon regained tolerance to thyroglobulin. By applying this theory and the results of these experiments to hydralazine induction of SLE and using the data acquired in the present experiments, it would be expected that in humans, B-lymphocyte populations arise which are responsive to DNA but because of T-lymphocyte unresponsiveness, immune reactions do not occur. Hydralazine, as was demonstrated in these experiments, is cross-reactive with DNA. When it is administered to man orally, or to a rabbit by injection, antibody formation to hydralazine can occur with T lymphocytes being activated by hydralazine. Because of the cross-reactivity between hydralazine and DNA, immune reactions are mounted to DNA. However, the antibodies resulting from such immune reactions should be capable of being completely absorbed with hydralazine (according to Weigle's experiments) as they were in our experiments. This necessity for extensive T-lymphocyte activation was demonstrated by the failure to find DNA antibodies in rabbits immunized with hydralazine25-RSA. When hydralazine is discontinued in man or the injections stopped in rabbits, then tolerance to DNA eventually recurs. Although this point was not dramatically made in our experiments, the DNA antibody titers fell when the inj ections were discontinued for a period of 5 wk. If the injections had been permanently discontinued, the titers might have disappeared. In the human with hydralazine-induced SLE with discontinuation of the hydralazine, it would be expected, from Weigle's experiments, that the syndrome would remit, and this has usually been the case. In spontaneous SLE, the cross-reactive antigen(s), if it exists, is at present unknown.
The role of genetic factors was not evaluated in our experiments as the rabbits were outbred. However, hydralazine-induced human SLE may have genetic factors involved as it primarily occurs in Caucasians who are slow acetylators (2) . Ongoing and future experiments in our laboratory are addressing this problem of possible genetic factors. It is hoped that this hydralazine-induced "serological SLE" may prove useful in future elucidation of the pathogenetic factors causing human SLE.
